Evan Seigerman
Stock Analyst at BMO Capital
(3.77)
# 770
Out of 4,711 analysts
138
Total ratings
50.55%
Success rate
8.1%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $566 → $520 | $397.27 | +30.89% | 14 | Dec 20, 2024 | |
| BIIB Biogen | Downgrades: Market Perform | $230 → $164 | $146.47 | +11.97% | 25 | Dec 20, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $57.33 | +6.40% | 11 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $94 → $102 | $92.57 | +10.19% | 14 | Nov 7, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $68.84 | -24.46% | 12 | Oct 30, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $128 → $114 | $135.42 | -15.82% | 14 | Oct 17, 2024 | |
| LLY Eli Lilly | Maintains: Outperform | $1,001 → $1,101 | $767.76 | +43.40% | 8 | Aug 9, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $64.50 | +8.53% | 5 | Jun 17, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $27.90 | +43.37% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $12.49 | +220.26% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $701.85 | +12.27% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.68 | -6.72% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $263.38 | -7.74% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $8.75 | +37.14% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $26.36 | +127.62% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.55 | +1,641.94% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $3.18 | +843.40% | 3 | May 12, 2020 |
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Outperform
Price Target: $566 → $520
Current: $397.27
Upside: +30.89%
Biogen
Dec 20, 2024
Downgrades: Market Perform
Price Target: $230 → $164
Current: $146.47
Upside: +11.97%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $57.33
Upside: +6.40%
Gilead Sciences
Nov 7, 2024
Maintains: Outperform
Price Target: $94 → $102
Current: $92.57
Upside: +10.19%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $68.84
Upside: -24.46%
Neurocrine Biosciences
Oct 17, 2024
Maintains: Market Perform
Price Target: $128 → $114
Current: $135.42
Upside: -15.82%
Eli Lilly
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $767.76
Upside: +43.40%
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $64.50
Upside: +8.53%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $27.90
Upside: +43.37%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $12.49
Upside: +220.26%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $701.85
Upside: +12.27%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.68
Upside: -6.72%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $263.38
Upside: -7.74%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $8.75
Upside: +37.14%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $26.36
Upside: +127.62%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.55
Upside: +1,641.94%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $3.18
Upside: +843.40%